{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:51:34Z","timestamp":1777852294284,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RO1 DA041367"],"award-info":[{"award-number":["RO1 DA041367"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Hum Lact"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Breastfeeding among lactating people with opioid use disorder taking buprenorphine monotherapy is generally accepted, as low concentrations of buprenorphine and metabolites in human milk have been well-established. The use of buprenorphine-naloxone for pregnant and lactating people with opioid use disorder is expanding and there is no information available regarding the concentrations of naloxone and their metabolites in human milk to recommend the use of this combination medication during lactation<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research Aims:<\/jats:title>\n                    <jats:p>To determine the concentrations of buprenorphine and naloxone and their primary metabolites in human milk, maternal plasma, and infant plasma, among lactating buprenorphine-naloxone maintained people and their infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Four lactating buprenorphine-naloxone maintained people provided plasma and human milk samples on Days 2, 3, 4, 14, and 30 postpartum. Infant plasma was obtained on Day 14.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Concentrations of buprenorphine, norbuprenorphine and their glucuronide metabolites were present in maternal plasma and human milk at low concentrations, consistent with previous research in lactating buprenorphine monotherapy participants. Naloxone was not detected, or was detected at concentrations below the limit of quantification, in maternal plasma and in all except one human milk sample at Day 30. Naloxone was not detected or detected at concentrations below the limit of quantification in all infant plasma samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Results support the use of buprenorphine-naloxone by lactating people who meet appropriate criteria for breastfeeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08903344231209304","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T06:32:49Z","timestamp":1701239569000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Buprenorphine-Naloxone Maintenance and Lactation"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-6142","authenticated-orcid":false,"given":"Lauren M.","family":"Jansson","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystle","family":"McConnell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Velez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Nursing, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munchelou","family":"Gomonit","sequence":"additional","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine J.","family":"Swortwood","sequence":"additional","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Dahan A. Aarts L. Smith T. W. (2010). Incidence reversal and prevention of opioid-induced respiratory depression. Anesthesiology 112(1) 226\u2013238. https:\/\/doi.org\/10.1097\/ALN.0b013e3181c38c25","DOI":"10.1097\/ALN.0b013e3181c38c25"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Dahan A. Yassen A. Romberg R. Sarton E. Teppema L. Olofsen E. Danhof M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. British Journal of Anaesthesia 96(5) 627\u2013632. https:\/\/doi.org\/10.1093\/bja\/ael051","DOI":"10.1093\/bja\/ael051"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Debelak K. Morrone W. R. O\u2019Grady K. E. Jones H. E. (2013). Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy: Initial patient care and outcome data. American Journal of Addiction 22(3) 252\u2013254. https:\/\/doi.org\/10.1111\/j.1521-0391.2012.12005.x","DOI":"10.1111\/j.1521-0391.2012.12005.x"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Harris D. S. Jones R. T. Welm S. Upton R. A. Lin E. Mendelson J. (2000). Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug and Alcohol Dependence 61(1) 85\u201394. https:\/\/doi.org\/10.1016\/s0376-8716(00)00126-5","DOI":"10.1016\/S0376-8716(00)00126-5"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Ilett K. F. Hackett L. P. Gower S. Doherty D. A. Hamilton D. Bartu A. E. (2012). Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via human milk during maternal buprenorphine substitution treatment. Breastfeeding Medicine 7 269\u2013274. https:\/\/doi.org\/10.1089\/bfm.2011.0096","DOI":"10.1089\/bfm.2011.0096"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Jansson L. M. Spencer N. McConnell K. Velez M. Tuten M. Harrow C. A. Jones H. E. Swortwood M. J. Barnes A. J. Scheidweiler K. B. Huestis M. A. (2016). Maternal buprenorphine maintenance and lactation. Journal of Human Lactation 32(4) 675\u2013681. https:\/\/doi.org\/10.1177\/0890334416663198","DOI":"10.1177\/0890334416663198"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Jones H. E. Kaltenbach K. Heil S. H. Stine S. M. Coyle M. G. Arria A. M. O\u2019Grady K. E. Selby P. Martin P. R. Fischer G. (2010). NAS after methadone or buprenorphine exposure. New England Journal of Medicine 363(24) 2320\u20132331. https:\/\/doi.org\/10.1056\/NEJMoa1005359","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_3_2_9_1","unstructured":"LactMed. (2023). Drugs and lactation database (LactMed\u00ae). Retrieved April 18 2023 from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501681\/"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Link H. M. Jones H. Miller L. Kaltenbach K. Seligman N. (2020). Buprenorphine-naloxone use in pregnancy: A systematic review and metaanalysis. American Journal of Obstetrics and Gynecology MFM 2(3) Article 100179. https:\/\/doi.org\/10.1016\/j.ajogmf.2020.100179.","DOI":"10.1016\/j.ajogmf.2020.100179"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Lund I. O. Fischer G. Welle-Strand G. K. O\u2019Grady K. E. Debelak K. Morrone W. R. Jones H. E. (2013). A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes. Substance Abuse 7 61\u201374. https:\/\/doi.org\/10.4137\/SART.S10955","DOI":"10.4137\/SART.S10955"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Mullins N. Galvin S. L. Ramage M. Gannon M. Lorenz K. Sager B. Coulson C. C. (2020). Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: A cohort study. Journal of Addiction Medicine 14(3) 185\u2013192. https:\/\/doi.org\/10.1097\/ADM.0000000000000562","DOI":"10.1097\/ADM.0000000000000562"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Ordean A. Tubman-Broeren M. (2023). Safety and efficacy of buprenorphine-naloxone in pregnancy: A systematic review of the literature. Pathophysiology 30(1) 27\u201336. https:\/\/doi.org\/10.3390\/pathophysiology30010004","DOI":"10.3390\/pathophysiology30010004"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Reece-Stremtan S. Marinelli K. A. (2015). ABM clinical protocol #21: Guidelines for breastfeeding and substance use or substance use disorder revised 2015. Breastfeeding Medicine 10(3) 135\u2013141. https:\/\/doi.org\/10.1089\/bfm.2015.9992","DOI":"10.1089\/bfm.2015.9992"},{"key":"e_1_3_2_15_1","volume-title":"Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants","author":"Substance Abuse and Mental Health Services Administration","year":"2018","unstructured":"Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants (HHS Publication No. [SMA] 18-5054). Substance Abuse and Mental Health Services Administration. store.samhsa.gov\/sites\/default\/files\/d7\/priv\/sma18-5054.pdf"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Swortwood M. J. Scheidweiler K. B. Barnes A. J. Jansson L. M. Huestis M. A. (2016). Simultaneous quantification of buprenorphine naloxone and Phase I and II metabolites in plasma and human milk by LC-MS\/MS. Journal of Chromatography A 1446 70\u201377. https:\/\/doi.org\/10.1089\/bfm.2015.9992","DOI":"10.1016\/j.chroma.2016.03.076"},{"key":"e_1_3_2_17_1","unstructured":"U.S. Food and Drug Administration\/Center for Drug Evaluation and Research. (2002). Clinical pharmacology and biopharmaceutics review. Suboxone\u00ae (Buprenorphine HCl\/Naloxone HCl) 2 mg\/0.5 mg 8 mg\/2 mg SublingualTablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/20-733_Subutex_BioPharmr.pdf"}],"container-title":["Journal of Human Lactation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344231209304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08903344231209304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344231209304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:34:11Z","timestamp":1777502051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08903344231209304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/08903344231209304"],"URL":"https:\/\/doi.org\/10.1177\/08903344231209304","relation":{},"ISSN":["0890-3344","1552-5732"],"issn-type":[{"value":"0890-3344","type":"print"},{"value":"1552-5732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}